middle.news
Neurotech’s NTI164 Clears Key Safety Hurdle in 90-Day Toxicology Study
9:56am on Monday 23rd of February, 2026 AEDT
•
Healthcare
Read Story
Neurotech’s NTI164 Clears Key Safety Hurdle in 90-Day Toxicology Study
9:56am on Monday 23rd of February, 2026 AEDT
Key Points
NTI164 well tolerated in 90-day GLP toxicology study with no mortality
Highest dose tested was 10 times greater than prior human doses
No clinically meaningful adverse effects on health markers observed
FDA-guided brain assessments revealed no neurological safety concerns
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEUROTECH INTERNATIONAL (ASX:NTI)
OPEN ARTICLE